Universität zu Köln

von Tresckow, Bastian and Moskowitz, Craig H. (2016). Treatment of relapsed and refractory Hodgkin Lymphoma. Semin. Hematol., 53 (3). S. 180 - 186. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1532-8686

Full text not available from this repository.

Abstract

Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%-20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. The anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) has been shown to induce high response rates in these patients; however, durable responses were reported in a small percentage of patients only. For carefully selected patients with multiple relapses, dose-reduced allogeneic transplant (RICallo) is a potentially curative option. The role of RICallo will have to be re-evaluated in the era of anti-programmed death-1 (PD1) antibodies. (C) 2016 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Moskowitz, Craig H. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-270444
DOI:	10.1053/j.seminhematol.2016.05.010
Journal or Publication Title:	Semin. Hematol.
Volume:	53
Number:	3
Page Range:	S. 180 - 186
Date:	2016
Publisher:	W B SAUNDERS CO-ELSEVIER INC
Place of Publication:	PHILADELPHIA
ISSN:	1532-8686
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMORADIOTHERAPY; BRENTUXIMAB VEDOTIN; PROGNOSTIC-FACTORS; SALVAGE THERAPY; PHASE-II; AUTOLOGOUS TRANSPLANTATION; EUROPEAN GROUP; WORKING PARTY; FREE SURVIVAL Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27044